본문 바로가기
KERD
논문KCI 등재

폐렴구균백신의 효과

Efficacy of Pneumococcal Vaccines

박호선
영남대학교 의과대학 (Yeungnam University College of Medicine)|2012.06|Journal of Yeungnam Medical Science|제29권 제1호|pp. 1-8

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

EfficacySystemic reviewPneumococcal vaccine
주제분류의학일반

초록

Streptococcus pneumonia is a very important pathogen for children and elderly people. Two types of pneumococcal vaccines are available in the market: pneumococcal polysaccharide vaccine (PPSV) and pneumococcal conjugate vaccine (PCV). PPSVs have been used for more than 30 years, and PCVs for about 10 years. There have been many reports concerning the evaluation of the vaccines’ efficacies in preventing pneumococcal diseases such as meningitis, pneumonia, and otitis media and bacteremia, but the clinical trials had been performed with different conditions, such as diverse vaccine valencies, age groups, races, target outcomes, immunological cut-off values, and follow-up periods. PPSV is recommended for elderly people and chronic disease patients such as asthma, diabetes mellitus, chronic renal failure, and hyposplenic patients. According to the data from several systemic reviews and population-based surveillances, PPSV is effective for pneumococcal pneumonia and vaccine-type bacteremia among healthy adults. Until now, however, there is insufficient evidence of the effectiveness of PPSV among high-risk adults. PCV is very effective in preventing vaccine-type invasive pneumococcal disease (IPD) among children, but its efficacy for pneumonia is very low among children. The incidence of vaccine-related or non-vaccine-type IPDs is increasing after the introduction of 7-valent PCV (PCV7) as a routine immunization for children. Recently, 10- and 13-valent PCVs have been used for children, instead of PCV7. Therefore, continuous surveillance for serotype change among pneumococcal diseases is necessary to evaluate the vaccines’ efficacy.

Abstract

Streptococcus pneumonia is a very important pathogen for children and elderly people. Two types of pneumococcal vaccines are available in the market: pneumococcal polysaccharide vaccine (PPSV) and pneumococcal conjugate vaccine (PCV). PPSVs have been used for more than 30 years, and PCVs for about 10 years. There have been many reports concerning the evaluation of the vaccines’ efficacies in preventing pneumococcal diseases such as meningitis, pneumonia, and otitis media and bacteremia, but the clinical trials had been performed with different conditions, such as diverse vaccine valencies, age groups, races, target outcomes, immunological cut-off values, and follow-up periods. PPSV is recommended for elderly people and chronic disease patients such as asthma, diabetes mellitus, chronic renal failure, and hyposplenic patients. According to the data from several systemic reviews and population-based surveillances, PPSV is effective for pneumococcal pneumonia and vaccine-type bacteremia among healthy adults. Until now, however, there is insufficient evidence of the effectiveness of PPSV among high-risk adults. PCV is very effective in preventing vaccine-type invasive pneumococcal disease (IPD) among children, but its efficacy for pneumonia is very low among children. The incidence of vaccine-related or non-vaccine-type IPDs is increasing after the introduction of 7-valent PCV (PCV7) as a routine immunization for children. Recently, 10- and 13-valent PCVs have been used for children, instead of PCV7. Therefore, continuous surveillance for serotype change among pneumococcal diseases is necessary to evaluate the vaccines’ efficacy.

참고문헌 (54)

  1. Cho JB, "A clinical observation on purulent meningitis in infancy and childhood", J Korean Pediatr Soc, 15, pp.54~62 (1972)
  2. Lee SH, "Clinical studies of purulent meningitis in infants and children", J Korean Pediatr Soc, 18, pp.568~576 (1976)
  3. Chang SH, "Clinical studies of purulent meningitis in infants and children", J Korean Pediatr Soc, 25, pp.304~314 (1983)
  4. Kim HK, "Cerebrospinal fluid lymphocytosis in acute bacterial meningitis on children", J Korean Pediatr Soc, 31, pp.707~714 (1988)
  5. Park JK, "A clinical observation on meningitis in infancy and childhood", J Korean Pediatr Soc, 27, pp.554~562 (1984)
  6. Lee BH, "Clinical observations of meningitis", J Korean Pediatr Soc, 32, pp.180~190 (1989)
  7. Lee CO, "Clinical studies of meningitis cases in children", J Korean Pediatr Soc, 34, pp.206~216 (1991)
  8. Kim KH, "The causative organisms of bacterial meningitis in Korean children, 1986-1995", J Korean Med Sci, 13, pp.60~64 (1998)
  9. 김현정, "소아 세균성 수막염에서 원인균에 관한 고찰(1992-2002)", Korean Journal of Pediatrics, 46(11), pp.1085~1088 (2003), 대한소아과학회
  10. Park DC, "Acute bacterial meningitis:causative organisms, clinical characteristics and prognosis", J Korean Neurol Assoc, 18, pp.556~561 (2000)
  11. 조성윤, "서울의 한 대학병원에서 경험한 소아의 세균성 수막염: 1993-2006", Korean Journal of Pediatrics, 51(10), pp.1077~1084 (2008), 대한소아과학회
  12. Lee HJ, "Disease burden of pneumococcal infection and serotypes of streptococcus pneumoniae in Korean children" (2007), Korea Centers for Disease Control and Prevention
  13. Woo JH, "A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology", Korean J Infect Dis, 33, pp.1~7 (2001)
  14. Kim JS, "Incidence of haemophilus influenzae type b and other invasive diseases in south Korean children", Vaccine, 22, pp.3952~3962 (2004)
  15. 김형태, "건강한 소아에서 지역사회 획득 균혈증의 원인균", Korean Journal of Pediatrics, 48(7), pp.716~722 (2005), 대한소아과학회
  16. 이용주, "대전·충청 지역의 소아 세균성 수막염에 대한 임상적 연구 : 2001-2005", Korean Journal of Pediatrics, 50(2), pp.157~162 (2007), 대한소아과학회
  17. 최원석, "국내 침습성 폐렴사슬알균 감염증의 임상양상", Infection and Chemotherapy, 42(3), pp.156~161 (2010), 대한감염학회
  18. Kim MJ, "Disease burden of pneumococcal infection and serotype of streptococcus pneumoniae in Korean adults" (2008), Korea Centers for Disease Control and Prevention
  19. 정용필, "지역사회획득 폐렴의 원인 미생물에 대한 전향적 다기관 연구: 세균성 폐렴의 원인균 분석", Infection and Chemotherapy, 42(6), pp.397~403 (2010), 대한감염학회
  20. "Recommendation to assure the quality, safety and efficacy of pneumococcal conjugate vaccines" (2009)[URL]
  21. Black S, "Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente vaccine study center group", Pediatr Infect Dis J, 19, pp.187~195 (2000)
  22. Madhi SA, "Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine", Vaccine, 25, pp.2451~2457 (2007)
  23. Lucero MG, "Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines:a randomized, double-blind, placebo-controlled trial", Pediatr Infect Dis J, 28, pp.455~462 (2009)
  24. Siber GR, "Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies", Vaccine, 25, pp.3816~3826 (2007)
  25. Jódar L, "Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants", Vaccine, 21, pp.3265~3272 (2003)
  26. Lucero MG, "Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age", Cochrane Database Syst Rev, (4), pp.CD004977~ (2009)
  27. Pavia M, "Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis", Pediatrics, 123, pp.e1103~e1110 (2009)
  28. Theodoratou E, "The effect of haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality", Int J Epidemiol, 39(Suppl 1), pp.i172~i185 (2010)
  29. Hansen J, "Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using world health organization standardized interpretation of chest radiographs", Pediatr Infect Dis J, 25, pp.779~781 (2006)
  30. Lexau CA, "Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine", JAMA, 294, pp.2043~2051 (2005)
  31. Whitney CG, "Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease:a matched case-control study", Lancet, 368, pp.1495~1502 (2006)
  32. Pilishvili T, "Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine", J Infect Dis, 201, pp.32~41 (2010)
  33. Park SY, "Invasive pneumococcal infections among vaccinated children in the United States", J Pediatr, 156, pp.478~ (2010)
  34. Barricarte A, "Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study", Clin Infect Dis, 44, pp.1436~1441 (2007)
  35. Millar EV, "Pre- and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and white mountain apache communities", Clin Infect Dis, 51, pp.1258~1265 (2010)
  36. Miller E, "Herd immunity and serotype replacement 4 years after sevenvalent pneumococcal conjugate vaccination in England and Wales:an observational cohort study", Lancet Infect Dis, 11, pp.760~768 (2011)
  37. Rodenburg GD, "Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses", Vaccine, 28, pp.1391~1396 (2010)
  38. Lehmann D, "The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes", Clin Infect Dis, 50, pp.1477~1486 (2010)
  39. Vila-Corcoles A, "Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study", Vaccine, 27, pp.1504~1510 (2009)
  40. Vila-Corcoles A, "Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older", BMC Infect Dis, 10, pp.73~ (2010)
  41. Hutchison BG, "Clinical effectiveness of pneumococcal vaccine. meta-analysis", Can Fam Physician, 45, pp.2381~2393 (1999)
  42. Moore RA, "Are the pneumococcal polysaccharide vaccines effective? meta-analysis of the prospective trials", BMC Fam Pract, 1, pp.1~ (2000)
  43. Cornu C, "Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials", Vaccine, 19, pp.4780~4790 (2001)
  44. Watson L, "Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults", Vaccine, 20, pp.2166~2173 (2002)
  45. Moberley SA, "Vaccines for preventing pneumococcal infection in adults", Cochrane Database Syst Rev, (1), pp.CD000422~ (2008)
  46. Huss A, "Efficacy of pneumococcal vaccination in adults: a meta-analysis", CMAJ, 180, pp.48~58 (2009)
  47. Sheikh A, "Pneumococcal vaccine for asthma", Cochrane Database Syst Rev, (1), pp.CD002165~ (2010)
  48. Conaty S, "The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials", Vaccine, 22, pp.3214~3224 (2004)
  49. Chong Y, "Capsular types and antimicrobial resistance of streptococcus pneumoniae isolated in Korea", Eur J Clin Microbiol Infect Dis, 14, pp.528~531 (1995)
  50. Park JY, "Serotypes and antimicrobial susceptibilities of streptococcus pneumoniae isolated from the clinical specimen", Korean J Infect Dis, 26, pp.9~19 (1994)
  51. 이택진, "단일기관에서의 소아 세균성 수막염 원인균 분포 (1996∼2005)", Pediatric Infection and Vaccine, 13(2), pp.124~129 (2006), 대한소아감염학회
  52. 김소희, "15년간(1991∼2005년) 우리나라 소아에서 분리된 폐구균의 혈청형 분포의 변화", Pediatric Infection and Vaccine, 13(2), pp.89~98 (2006), 대한소아감염학회
  53. 이택진, "중이염 환아의 이루에서 분리된 폐구균의 혈청형 분포(2001-2006)", Pediatric Infection and Vaccine, 15(1), pp.44~50 (2008), 대한소아감염학회
  54. Plan for the evaluation of usefulness of vaccines that are not included in the national immunization program, "Park HS", National Institute of Food and Drug Safety Evaluation, 90~94 (2011)

관련 논문AI추천

Pneumococcal Vaccination in Korean Adults: 2025 Recommendations by the Korean Society of Infectious DiseasesChoi Jun Yong, Choi Min Joo, Choi Won Suk, Choo Eun Ju, Heo Jung Yeon, Kwon Ki Tae, Noh Ji Yun, Park Sun Hee, Park Wan Beom, Song Joon Young대한감염학회 · Infection and Chemotherapy2025 · 제57권 제3호소아의 중이염 및 폐렴 예방을 위한 백신이환종대한소아감염학회 · Pediatric Infection and Vaccine2009 · 제16권 제1호국내 침습성 폐렴사슬알균 감염증의 임상양상김미정, 김민자, 김우주, 김정연, 노지윤, 박대원, 송준영, 윤영경, 정희진, 조유미, 최원석, 허중연대한감염학회 · Infection and Chemotherapy2010 · 제42권 제3호Invasive Pneumococcal Diseases in Korean Adults After the Introduction of Pneumococcal Vaccine into the National Immunization Program이미숙대한감염학회 · Infection and Chemotherapy2023 · 제55권 제4호The Changing Epidemiology of Childhood Pneumococcal Disease in Korea이환종, 최영준, 최은화대한감염학회 · Infection and Chemotherapy2013 · 제45권 제2호폐렴원인균으로서 약제내성 폐렴사슬알균 (Drug-resistant Streptococcus pneumoniae )의 현황과 임상적 의미신경철영남대학교 의과대학 · Journal of Yeungnam Medical Science2011 · 제28권 제1호

이 간행물의 다른 논문 (14건)

폐절제술을 시행받은 환자의 수술 전후 관리이장훈pp. 9-13나선식 CT를 이용한 혐색소형 신세포암과 투명세포형 신세포암의 감별김홍철, 조재호pp. 14-18애디슨병 환자에게 리팜핀 투여 후 발생한 급성 부신피질기능 저하증 1예강종식, 고광범, 김선목, 이우제, 최광현, 전성진, 김민수, 이재준pp. 19-23A Case of Ruptured Mycotic Hepatic Artery Aneurysm Successfully Treated Using Arterial Embolization진영주, 이한주, 박지현, 이민정, 양지은, 이보영, 김기애pp. 24-27횡문근융해증과 경한 신손상을 동반한 급성 A형 간염 1예전부석, 조규민, 이창돈, 성현진, 심은희, 이석종, 김창욱, 허준, 이종환pp. 28-30
원문 보기